Infectious Complications of Ventricular Assist Device Use in Children in the US: Data from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) by Auerbach, Scott R. et al.
Infectious Complications of Ventricular Assist Device Use in Children in the US:  Data from the 
Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) 
Running Title: Infection in Pediatric Ventricular Assist Device Use 
Scott R. Auerbach, MD1, Marc E. Richmond, MD, MS2, Kurt R. Schumacher, MD, MS3, Dalia Lopez-
Colon, PhD4, Max B. Mitchell, MD5, M. W. Turrentine, MD6, Ryan S. Cantor, MSPH7, Robert A. Niebler, 
MD8, Pirooz Eghtesady, MD, PhD9.  
1Pediatrics, Division of Cardiology, University of Colorado Anschutz Medical Campus and Children’s 
Hospital Colorado, Aurora, CO, 2Division of Pediatric Cardiology, Columbia University, New York, NY, 
3Pediatrics, Cardiology, University of Michigan, Ann Arbor, MI, 4Pediatrics, Congenital Heart Center, 
University of Florida, Gainesville, FL, 5Pediatric Cardiothoracic Surgery, University of Colorado Anschutz 
Medical Campus and Children’s Hospital Colorado, Aurora, CO, 6Department of Surgery, Division of 
Thoracic and Cardiovascular Surgery, Indiana University School of Medicine, Indianapolis, IN, 7Kirklin 
Institute for Research in Surgical Outcomes, The University of Alabama at Birmingham, AL, 8Pediatrics, 
Medical College of Wisconsin, Milwaukee, WI, 9Surgery – Cardiothoracic, Washington University School 
of Medicine, St. Louis, MO 
Correspondence/Reprint Requests: 
Scott Auerbach, M.D 
Associate Professor of Pediatrics 
Medical Director, VAD Program 
University of Colorado Anschutz Medical Campus 
Children’s Hospital Colorado Heart Institute 
13123 East 16th Avenue 
Aurora, CO 80045 
Key Words: ventricular assist device, adverse events, continuous-flow device, Pulsatile-flow 
device, infection 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Auerbach, S. R., Richmond, M. E., Schumacher, K. R., Lopez-Colon, D., Mitchell, M. B., Turrentine, M. W., … Eghtesady, P. (2017). 
Infectious Complications of Ventricular Assist Device Use in Children in the US: Data from the Pediatric Interagency Registry for 
Mechanical Circulatory Support (Pedimacs). The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2017.09.013
                          
2 
 
This work was presented at the International Society for Heart and Lung Transplantation 
Conference on April 28th, 2016. 
Background:  Infections are frequent in pediatric ventricular assist device (VAD) patients. We aimed to 
describe infections in durable VAD patients reported to Pedimacs. 
Methods: Durable VAD data from the Pedimacs registry (9/19/2012-12/31/2015) were analyzed. 
Infections were described with standard descriptive statistics, Kaplan-Meier analysis, and competing 
outcomes analysis.  
Results:  There were 248 implants in 222 patients with a mean age and a median follow-up of 11±6.4 
years and 2.4 patient-months (<1 day-2.6 year), respectively.  Device types were pulsatile flow (PF) in 91 
(41%) patients and continuous flow (CF) in 131 (59%) patients. PF patients were younger (4±4 vs 14±4 
yr; p<0.0001) and were more likely to have congenital heart disease (25% vs 12%; p=0.03), prior surgery 
(53% vs 26%; p<0.0001), and prior ECMO (24% vs 7%; p=0.0003).  Infection accounted for 17% (96/564) 
of reported adverse events (AE).  A non-device infection was most common (51%), followed by sepsis 
(24%), external pump component infection (20%), and internal pump component infection (5%). Most 
infections were bacterial (73%) and required IV therapy only (77%). The risk of infection in the constant 
phase was higher in patients with a history of prior infection and in patients with a history of a non-
infectious major AE.  Survival was lower following infection only in CF patients (p=0.008).  
Conclusions: 
Infection was the most common AE after pediatric VAD implantation.  Non-device infections were most 
common. The best predictor of a future infection was a past infection. CF patients have higher risk of 
death after an infection. 
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Introduction 
The use of ventricular assist devices (VAD) in children has increased dramatically over the last decade in 
both children and adults, with a marked improvement in survival to transplantation1-5. However, adverse 
events (AE) remain a common problem following device placement5-7. Our ability to minimize AE 
depends on a thorough understanding of the event rates, event severity, risk factors for AE, and 
associations between various AE. Infectious complications are one of the most common AE related to 
pediatric VAD use. Adult studies have shown the infection rate to be 8.2 per 100 pt-months5. 
Retrospective and prospective studies of pediatric VAD use have reported that 40-63% of patients 
develop an infection while on VAD support 8-11. Retrospective studies of pediatric VAD use have shown 
rates of infection of 1.5-5.4 infections per 100 VAD days (46-164 infections per 100 pt-months) for the 
Berlin Heart EXCOR and have shown thromboembolic events to be associated with infection8, 11. A study 
comparing outcomes and AE of continuous flow VADs in children and adults reported infection rates of 
1.12 and 0.97 infections per pt-year (9.3 and 8.1 infections per 100 pt-months) in children and adults, 
respectively, and non-device infections were most common12. In a recent analysis of the Pedimacs 
registry, there were 263 AE in 135 patients, of which 19.8% were due to infection. The early infection 
rate (within 3 months post-implant) was 15.0 events per 100 pt-months and the late infection rate (after 
3 months) was 2.3 events per 100 pt-months10. However, details about the types of infection were not 
reported and further information about infectious complications is needed to help guide management 
decisions in pediatric patients.  A detailed analysis of the Pedimacs registry will provide beneficial data 
on the types of and risks for infectious complications observed in children. The objective of this 
manuscript is to expand on the first contemporary, national-level description of the adverse events 
associated with the full spectrum of pediatric VAD use in the United States by providing a detailed 
description and analysis of infectious adverse events (IAE).
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Methods: 
The Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) is a National 
Institutes of Health funded, U.S. national registry of patients supported by FDA-approved VAD, which 
now contains data on >15,000 patients5. Pedimacs, the pediatric component of Intermacs, began 
enrolling pediatric patients supported with VAD on September1, 2012 and at the time of this analysis 
included data from 41 centers. The Pedimacs registry has been previously described in detail13. 
Pedimacs enrolled 275 prospective patients implanted between September 19, 2012 and December 31, 
2015. For this study, we included patients receiving at least one long-term device and excluded patients 
that received either a temporary support device or a total artificial heart. 
 
AE in Pedimacs are categorized using a pre-specified dictionary of adverse events that is provided to 
each participating site.  The definitions were derived by expert consensus, working in large part from the 
definitions already employed in Intermacs, and altering them as necessary to be appropriate for 
pediatric patients.  Pedimacs AE have been previously described and entire list of AE used in Pedimacs 
and their definitions can be reviewed on the Pedimacs website 
(https://www.uab.edu/medicine/intermacs/appendices-5-ped/appendix-a-adverse-event-definitions)14. 
Pedimacs major AE (MAE) for this analysis are defined as major infection, device malfunction, major 
bleeding, and neurologic dysfunction. A major infection or infectious AE is defined as “a clinical infection 
accompanied by pain, fever, drainage and/or leukocytosis that is treated by anti-microbial agents (non-
prophylactic).  A positive culture from the infected site or organ should be present unless strong clinical 
evidence indicates the need for treatment despite negative cultures.” Definitions of infectious AE 
locations are as follows: 
1. Localized Non-Device Infection:  Infection localized to any organ system or region without 
evidence of systemic involvement (see sepsis definition), ascertained by standard clinical 
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methods and either associated with evidence of bacterial, viral, fungal or protozoal 
infection, and/or requiring empirical treatment.  
2. External Pump Component:  A positive culture from the skin and/or tissue surrounding the 
drive line or from the tissue surrounding the external housing of a pump implanted within 
the body, coupled with the need to treat with antimicrobial therapy, when there is clinical 
evidence of infection such as pain, fever, drainage, or leukocytosis. For the purposes of this 
analysis, an infection location designated as mediastinum was considered an external pump 
component infection rather than localized non-device infection. This location refers to 
an infection of the device that is not in contact with the blood-device interface. 
3. Internal Pump Component, Inflow or Outflow Tract Infection:  Infection of blood-contacting 
surfaces of the LVAD documented by positive site culture.   
4. Sepsis:  Evidence of systemic involvement by infection, manifested by positive blood 
cultures and/or hypotension. 
To determine the effect of prior major AE on subsequent AE we have segmented the patient follow-up 
times into intervals at each major AE and devised two covariates defined for each segment. 
 
1) History of Prior Infectious AE. A patient’s history of infectious AE was determined at the time of 
infection event. For example, the first infection event would be one without any other prior 
infection event. All subsequent infection events would be classified as having a history of 
infection. 
 
2) History of Non-Infection Major AE. A patient’s history of at least one major non-infection 
adverse event (bleeding, device malfunction, neurological dysfunction) was determined for each 
time segment.   
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Statistical Analysis 
Patient characteristics were evaluated using descriptive statistics. Continuous variables were described 
as means with standard deviations (and analyzed using t-tests) or median with interquartile range [IQR] 
(and analyzed with the Mann-Whitney U test), as appropriate. Categorical variables were described as 
counts and percentages and compared using chi-squared or Fisher’s exact test. Infectious AE were 
categorized based on location: localized non-device (pulmonary, urinary tract, peripheral wound, 
gastrointestinal, unknown, and other); external pump component (driveline, exit cannula, 
mediastinum); internal pump component (pump interior, pump pocket); or sepsis (positive blood 
cultures, line sepsis). The timing of the infectious AE was categorized as early if it occurred within 3 
months after an implant and late if it occurred more than 3 months after an implant, consistent with 
other reporting in both Intermacs and Pedimacs. Multiple events were allowed for patients. Early and 
late infectious AE rates were calculated overall and for each infection category. Time to first infectious 
AE was determined using Kaplan Meier survival comparison between groups using the log rank test. 
Competing outcomes methodology was used to calculate the time-related probability of patients having 
an infectious AE, being alive and on support and free of infectious AE, receiving a heart transplant 
without infection, or recovery free from infectious AE. To determine the effect of infectious AE on 
subsequent survival, Kaplan Meier estimates for survival on a device were calculated for patients 
without or prior to an infectious AE (censoring at transplant, recovery, or first infection) and compared 
with estimates based on survival on a device after the first infectious AE15. Associations between 
infectious AE and major AE were determined with multi-phase, parametric hazard modeling using time-
varying covariates for this history of MAE or the history of IAE. This parametric model included an early 
decreasing phase of hazard in addition of a constant hazard. The model was adjusted also for flow type 
of the device (PF or CF). There were 2 major AE on the day of device implant that were not used for 
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analysis of associations between infectious AE and major AE. Pedimacs defines major AE as bleeding, 
infection, neurologic event, and device malfunction. All analyses were conducted using SAS 9.4. 
 
Results: 
Patient Enrollment and Characteristics 
There were 275 patients enrolled in Pedimacs during the study period, of whom 222 received a 
durable device and were included in this cohort. There were 46 patients on temporary support and 7 on 
total artificial heart support that were excluded. There were 131 patients (59%) that received a 
continuous flow device (CF) and 91 (41%) that received a pulsatile flow device (PF). The CF group 
consisted of 122 left ventricular assist devices (LVAD), 7 biventricular assist devices (BiVAD), and 2 right 
ventricular assist devices. The PF group consisted of 65 LVAD, 24 BiVAD, and 2 RVAD. The median time 
on a device was 2.6 patient-months (range <1 day – 2.6 years) with no difference in median time on 
device between CF and PF groups (2.5 months, IQR [1.2-5.6] vs. 1.9 months, IQR [0.8-5.2], respectively; 
p=0.16). This represented 73.4 patients-years with a durable device in place. 
 
Clinical characteristics are compared between patients with PF and CF devices in Table 1. There were 
significant differences between PF and CF patients. PF patients were significantly younger (p<0.001), 
more likely to have a diagnosis of congenital heart disease (P=0.029), have a smaller body surface area 
(p<0.001), have a history of extracorporeal membrane oxygenation (ECMO) prior to implantation 
(P=0.0003), and have a history of prior cardiac surgery (p<0.0001). Differences in laboratory data prior 
to implantation included the PF group having higher brain natriuretic and pro-brain natriuretic peptide 
levels (P=0.0003 and p=0.024, respectively) and higher white blood cell and lymphocyte counts 
(p=0.0007 and p=0.043, respectively. Variables for which there was no difference between groups 
included blood urea nitrogen, previous mechanical circulatory support device, aspartate or alanine 
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aminotransferases, albumin, pre-albumin, hemoglobin, platelet count, international normalized ratio, 
uric acid, eGFR, total bilirubin, and malnutrition/cachexia. 
 
Implant Characteristics were compared between PF and CF patients, as shown in Table 2. There were 
significant differences between PF and CF patients. PF patients were more likely to be classified as 
patient profile 1 rather than profiles 2-4 (P=0.0125), to have a device strategy of bridge to transplant vs. 
bridge to decision (p=0.0026), and to have BiVAD support vs. LVAD support (p<0.0001). 
 
Patient Survival 
As of December 31, 2015, there were 33 (14.9%) who were alive on a device, 143 (64.4%) who were 
transplanted, 34 (15.3%) who had died, and 3 (1.4%) who had recovered. The median time on a device 
was 2.4 patient-months (range <1 day – 2.7 years). This represented 73.4 patients-years with a durable 
device in place.  There was no difference in time on device between PF and CF groups (p=0.16). 
Competing outcomes analysis can be found in the online supplement (Supplemental Figures 1-3). The 
proportions of patients transplanted, alive on device, dead, and explanted at 6 months post-implant for 
PF device patients were 54.5%, 21.6%, 23.9%, and 0% and for CF device patients were 64.3%, 28%, 7.7%, 
and 0%.   
 
Rates of Infectious Adverse Events 
There were 59 patients who had at least one infectious AE (26.6%). There was a total of 95 infectious AE 
during the study period. Infectious AE represented 17% of all AE, making it the most common of all AE 
for this cohort. There were 34 patients (15.3%) with one infectious AE, 18 (8.1%) with 2 infectious AE, 
and 6 (3.2%) with ≥3 infectious AE. The 2 device types had a similar proportion of AE that were 
infectious, at 17% and 16% of AE in the PF and CF groups, respectively (p=0.9). Following infectious AE, 
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the next most frequent AE were device malfunction (14%) and major bleeding (13%). An infectious AE 
directly contributed to death in 5 patients (5%), including 3 (7%) PF patients and 2 (3%) CF patients.   
  
Infectious AE Rates by timing and location of infectious AE are shown in Table 3. Early infectious AE 
were more common than late infectious AE for all patients (14.5 vs 7.2 infectious AE per 100 patient-
months), for PF patients (18.0 vs 10.2 infectious AE per 100 patient-months), and for CF patients (12.3 vs 
6.3 infectious AE per 100 patient-months).  The most common infectious AE by location was localized 
non-device (49, 51%) followed by sepsis (23, 24%), external pump component (19, 20%), and internal 
pump component (5, 5%). While rates of overall early infectious AE were not statistically different 
between device types (18.0 vs 12.3 per 100 patient-months (p=0.12), there was a significantly higher 
rate of early sepsis in PF vs CF patients (6.4 vs 2.2 per 100 patient-months, respectively; (p=0.03). There 
were 12 infectious AE that occurred in the outpatient setting, all of which occurred in the CF group. 
Types of infectious AE seen in the outpatient setting included sepsis (N=4), drive line site infection (N=4), 
urinary tract infection (N=1), pneumonia (N=1), acute otitis media (N=1), and cellulitis (N=1).  
 
Characteristics of Infectious Adverse Events 
 
Table 4 shows the type of infectious agent responsible for infectious AE and the management of 
infectious AE. The type responsible for the infectious AE included bacterial (70 infectious AE, 73%) fungal 
(12 infectious AE, 12%), viral (8 infectious AE, 8%), and unknown (5 infectious AE, 5%). Management of 
infectious AE included intravenous drug therapy only (74 infectious AE, 77%), oral drug therapy (11 
infectious AE, 11%), surgical and drug therapy (8 infectious AE, 8%), and unknown (2 infectious AE, 2%). 
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Freedom from Infection 
Competing outcomes analyses including time to a first infectious AE by device type are shown in figure 
1A and 1B. At 6 months post-implant, a higher percentage of PF vs CF patients had experienced a first 
infectious AE 29.7% vs 21.2%, respectively) and a lower percentage of PF vs CF patients underwent 
transplantation without an infectious AE (42.7% vs 56.0%, respectively). 
 
Kaplan Meier survival analysis comparing freedom from infectious AE in all patients stratified by device 
type is shown in figure 2. While there was not a statistically significant difference in freedom from an 
infectious AE, the curves separate 2 months after implantation. Hazard modeling of the early and late 
phase show that the risk of infection in the early phase is not significantly different between device 
types (HR 0.7, 95% CI [0.1-3.2]). However, the risk of infectious AE in the late phase is significantly higher 
in the PF group (HR 2.6, 95% CI [1.2-6.0]). Freedom from first infectious AE stratified by patient profile 
was not associated with a lower freedom from infectious AE when comparing profile 1 to profiles 2-4 in 
either the PF or CF groups (p=0.43 and p=0.73, respectively). 
 
Survival on Device after an Infection 
Patient survival following a first infectious AE was significantly worse compared to survival in those 
without an infectious AE (p=0.042, Figure 3A). When this was evaluated by device type, there was not a 
significant difference in survival between patients with and without a prior infection in the pulsatile 
group (Figure 3B, p=0.77). However, survival was significantly worse in patients with CF devices 
following a first infection (Figure 3C, p=0.0076). 
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Associations Between Infectious AE and Major AE 
Table 5 shows the risk of infectious AE following a prior infectious AE and following a non-infectious 
MAE (after controlling for device type). A prior infectious AE was associated with a subsequent 
infectious AE only during the late phase (HR 1.9, 95% CI [1.0-3.4]; p=0.04). A history of a non-infectious 
MAE was also associated with a subsequent infectious AE (HR 1.9, 95% CI [1.0-3.8]; p=0.05).  
 
Discussion:  
The ability of VAD use to improve survival to transplant in children has been known for decades2, 
16. More recently, the development of Pedimacs has allowed for the study of VAD specific outcomes in a 
multicenter fashion. The initial Pedimacs reports showed excellent outcomes related to VAD use, but 
showed a significant number of AE17, 18. A subsequent, more detailed Pedimacs analysis of AE related to 
VAD use, showed that infection is one of the most frequent AE, along with device malfunction, bleeding 
and neurologic dysfunction. Due to the high rates of infectious AE in these previous reports, this analysis 
was proposed to obtain a better understanding of infectious AE in children on VAD support.  
This study demonstrated that infection is the most common AE following VAD placement, which 
is consistent with single center reports and earlier Pedimacs studies14, 19-21. This differs only slightly from 
adult Intermacs data, which showed that bleeding was the most common AE, while infectious AE were a 
very close second5.  We found that infectious AE occur more frequently in the early period after VAD 
implant, which is not surprising, as single center studies of VAD use in children have shown that the AE 
rate is highest in the first week after implantation21. Furthermore, adult data from Intermacs showed 
the peak hazard of infectious AE occurred in the early period after implant5. The early period after 
implantation is a time during which the VAD patient is more likely to be exposed to intensive care and 
have indwelling lines and catheters, while also being in a state of suboptimal nutrition. De-
intensification of patient care decreases the risk of infection and has usually been optimized by 3 
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months post-transplant.  While the calculated rates of infectious AE were slightly higher in PF patients in 
both the early and late period compared to the CF patients, we did not find a difference in freedom from 
infectious AE between the groups in the early phase. This was somewhat surprising given that there was 
a higher proportion of PF patients that were Intermacs Profile I and that required biventricular support. 
Given that there was lower survival in the pulsatile group, it is possible that patients most likely to 
develop an infectious AE died prior to the onset of an infectious AE.  With that in mind, it is not 
surprising that the risk of infection was higher in the pulsatile group in the late phase after VAD 
placement. Pedimacs PF patients are required to remain in the hospital for the duration of their VAD 
course and are exposed to the infectious risk associated with long term inpatient stays. The PF patients 
were younger, more likely to have been on BIVAD support, more likely to have been Intermacs Patient 
Profile I, and more likely to have undergone previous cardiac surgery, all of which make recovery, 
mobilization and rehabilitation more difficult and may explain the higher incidence of late infectious AE. 
Another notable finding is that the vast majority of infectious AE are not of the device itself, but 
are located elsewhere (pneumonia, line sepsis, urinary tract infection, gastroenteritis, etc.), These 
infections are a reflection of the chronic disease state of the patient. This finding is similar to single 
center pediatric studies showing that most infectious AE are caused by sepsis or localized non-device 
infection and Intermacs data showing that adult patients were most likely to develop pneumonia and 
sepsis before developing a percutaneous site infection21, 22.   
Approximately 2/3 of the infectious AE were able to be treated with medical therapy alone and 
only 3% required surgical intervention. The vast majority of the infections were bacterial in nature. The 
types of organisms causing infectious AE between groups was similar with the exception of a slightly 
higher proportion of fungal infections in the continuous flow group. The reason for this is unclear, but 
these infections were mostly non-device related. There were 9 total fungal infectious AE in the 
continuous flow group with the following sources:  pulmonary (N=5), urinary tract (N=1), bloodstream 
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(N=1), cellulitis (N=1), and mediastinum (N=1). None of these fungal infections required surgical 
intervention. Surgical intervention to treat an infectious AE was only required in 8 infectious AE (7 
patients). While not statistically significant due to the small N, there was a higher proportion of 
infectious AE were treated with surgery in the pulsatile group (14% vs 3%; p=0.07). These pump related 
infections may be due to a relatively larger device -patient interface in the PF patients.  
 
Overall, there was no difference in survival following a 1st infectious AE. However, when we 
separated patients by device type, survival was lower following a 1st infectious AE in continuous flow 
device patients compared to those without an infectious AE (Figure 3C). The reason for this is unclear 
but the finding mirrors Intermacs data showing that patients on CF devices with a history of a 
percutaneous site infection had lower survival after VAD implantation22. In our analysis, there were 7 
deaths following infectious AE and only 2 of those were felt to contribute to their death. While infection 
can certainly directly result in death, it may also be a surrogate for other complications or risk factors for 
death following device placement. The lack of difference in survival after a first infectious AE in the 
pulsatile group is likely due to the lower overall survival rate, resulting in lower potential to detect a 
difference is survival after infectious AE. Previous reports and Pedimacs data have shown that the most 
common causes of death in this group are not infectious, but rather due to neurologic injury, respiratory 
failure, bleeding, and multi-organ system failure23.  
 
We also found associations between MAE (infectious and non-infectious) and a subsequent 
infectious AE. After controlling for device type, a MAE was associated with a subsequent infectious AE in 
only in the late phase. The findings that both infectious and non-infectious MAE were associated with 
future infectious AE are not surprising as the conditions and risk factors that lead to the infectious AE 
often persist for months after VAD implantation.  
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This study has its limitations. Foremost, the analysis is limited by small numbers and, therefore, 
it is mostly descriptive in nature. For example, we were unable to determine whether BiVAD use 
resulted in a higher risk of infection and we were unable to properly model pre-transplant risk factors 
for infection due to lack of power.  This also limits the inference that can be drawn from the multivariate 
modeling, as only strong associations may be observed. Comparisons between pulsatile and continuous 
flow devices should be considered descriptive because of the significant differences in pre-implant 
characteristics between the groups. This analysis has been performed early in the Pedimacs experience 
and overtime a more robust database will allow us to power some of the analyses that we were unable 
to do at this time. Finally, the database only provides a category of infection (i.e. bacterial, viral, fungal, 
etc.) and does not provide data on specific organisms causing infection.  
 
 In summary, this is the first detailed analysis of infectious AE in pediatric VAD recipients using 
the Pedimacs registry.  Infectious AE are the most common AE seen in the population and most often 
occur in the early period post-implant. Most infections are not device related and can be treated with 
medical therapy. A previous MAE is predictive of future infectious AE and patients with CF devices who 
develop an infectious AE are at higher risk of death while on VAD support.  
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Figures: 
 
 
Figure 1.  Competing outcomes analysis with first infection as an outcome, separated by device type 
(pulsatile flow, 1A, and continuous flow, 1B). Outcomes include alive on device without infection, death 
before transplant without infection, transplanted without infection, explanted without infection, and 
first infection. 
 
Figure 2. Kaplan-Meier analysis showing time to first infectious adverse event of the entire cohort 
stratified by device type. 
 
Figure 3. Kaplan-Meier analysis utilizing a modulated renewal process comparing survival following a 
first infectious AE to survival in those without an infectious AE in all patients(5A), patients on PF devices 
(5B), and patients on CF devices (5C). 
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Table 1. Patient Characteristics Prior to Implantation 
Baseline Characteristics 
Pulsatile Flow, n=91 
 
Continuous Flow, n=131 
 p-value 
Age (y) ± std. dev. 3.7 ± 4.0 14.2 ± 3.5 <.0001 
Female, n(%) 43 (47.3) 46 (35.1) 0.07 
Cardiac Diagnosis, n(%)   0.03 
   1. Congenital Heart Disease 23 (25.3) 15 (11.6)  
   2. Dilated Myopathy 55 (60.4) 105 (81.4)  
   3. Hypertrophic Cardiomyopathy  2 ( 1.6)  
   4. Restrictive Cardiomyopathy 7 ( 7.7) 4 ( 3.1)  
   5. Post-Transplant/Graft Dysfunction 4 ( 4.4) 2 ( 1.6)  
   6. Coronary Artery Disease 1 ( 1.1)   
   7. Unknown 1 ( 1.1) 1 ( 0.8)  
   8. Cancer  1 (0.8)  
   9. Valvular Heart Disease  1 (0.8)  
Race, n(%)   0.56 
   African American 18 (19.8) 31 (23.7)  
   Other 13 (14.3) 23 (17.6)  
   White 60 (65.9) 77 (58.8)  
Body Surface Area ± std. dev. 0.6 ± 0.4 1.6 ± 0.4 <.0001 
Previous ECMO, n(%) 22 (24.2%) 9 (6.9%) 0.0003 
Previous Cardiac Surgery, n(%) 48 (52.7) 34 (26) <.0001 
Brain Natriuretic Peptide (pg/mL) ± std. dev. 2816.1 ± 1952.8* 1586.2 ± 1395.8* 0.0003 
Pro Brain Natriuretic Peptide (pg/mL) ± std. dev. 17992 ±15320* 10160 ± 9926.3* 0.02 
White Blood Cell Count (x103/µL) ± std. dev. 91, 12.2 ± 7.2 131, 9.6 ± 3.7 0.0007 
Lymphocyte Count (%)± std. dev. 24.9 ±15.6* 20.6 +/- 11.9* 0.04 
eGFR mL/min/1.73 m2 ± std. dev. 83.6 ± 40.6 83.7 ± 43.2 0.98 
Total Billirubin (mg/dL) ± std. dev. 1.4 ± 1.5* 1.6 ± 2.3* 0.64 
Malnutrition/cachexia 3 (3.3) 4 (3.1) 1.00 
Pulmonary hypertension, n(%) 3 (3.3) 15 (11.5) 0.03 
*Data points not available in all patients for this variable 
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Table 2. Implant Characteristics Comparing Pulsatile and Continuous Flow Devices 
 
Implant Characteristics 
Pulsatile Flow 
(n=91) 
Continuous Flow 
(n=131) p-value 
Patient Profile   0.01 
   1. Critical Cardiogenic Shock 30 (34.9) 21 (16.5)  
   2. Progressive Decline 47 (54.7) 82 (64.6)  
   3. Stable but Inotrope Dependent 6 ( 7.0) 19 (15.0)  
   4-7. Resting Symptoms or Less Sick 3 ( 3.5) 5 ( 3.9)  
Pre-Implant Device Strategy   0.003 
   1. Bridge to Transplant - Listed 70 (76.9) 69 (52.7)  
   2. Bridge to Candidacy 18 (19.8) 55 (42.0)  
   3. Destination Therapy 2 ( 2.2) 5 ( 3.8)  
   4. Bridge to Recovery  2 ( 1.5)  
   5. Other 1 ( 1.1)   
Pre-Implant Device Type   <.0001 
   1. LVAD 65 (71.4) 122 (93.1)  
   2. RVAD 2 ( 2.2) 2 ( 1.5)  
   3. BiVAD 24 (26.4) 7 ( 5.3)  
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Table 3. Infection Rates by Timing and Location of Infection 
       
                             Overall         Pulsatile Flow     Continuous Flow 
  Events Patients Rate1 Events Patients Rate1 Events Patients Rate1 
All Infections                   
      Early 63 45 14.5 30 22 17.4 33 23 12.3 
      Late 32 21 7.2 11 8 10.2 21 13 6.3 
Localized Non-Device 
Infection                   
      Early 38 27 8.6 15 10 8.7 23 17 8.5 
      Late 11 9 2.5 6 5 5.5 5 4 1.5 
External Pump Component                   
      Early 6 5 1.4 2 2 1.2 4 3 1.5 
      Late 13 10 2.9 4 3 3.7 9 7 2.7 
Internal Pump Component                   
     Early 2 2 0.5 2 2 1.2 0 0 0 
     Late 2 2 0.5 1 1 0.9 1 1 0.3 
Sepsis                   
     Early 17 17 3.9 11 11 6.4 6 6 2.2 
     Late 6 5 1.4 0 0 0 6 5 1.8 
1
Rate are per 100 patient-months 
   Overall Follow-Up Time: Early 441.5, Late 443.6 (per 100 patient-months) 
 Pulsatile Follow-Up Time: Early 172.3, Late 108.2 (per 100 patient-months) 
 Continuous Follow-Up Time: Early 269.3, Late 335.4 (per 100 patient-months) 
Early events occurred within 3 months of 
implant 
  Late events occurred more than 3 months after implant 
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Table 4. Infectious Adverse Events: Organisms and Management 
 
  
       Pulsatile Flow 
      Continuous 
Flow              All 
Infection 
Events 
% of 
Infection 
Events 
Infection 
Events 
% of 
Infection 
Events 
Infection 
Events 
% of 
Infection 
Events 
Infection Type 
35 85% 35 64% 70 73%    Bacterial 
   Fungal 3 7% 9 16% 12 12% 
   Viral 3 7% 5 9% 8 8% 
   Unknown . . 5 9% 5 5% 
Adverse Event Infection Intervention 
4 9% 7 12% 11 11%    Drug therapy only: Oral 
   Surgical and drug therapy 6 14% 2 3% 8 8% 
   Drug therapy only: IV 31 75% 43 79% 74 77% 
   Unknown . . 2 3% 2 2% 
   All 41 100% 54 100% 95 100% 
  
  
       
 
 
Table 5. Association of Infectious Adverse Events with Other Major Adverse Events 
 
 Early Phasea Constant Phaseb 
 HR (95% CI) p-value HR (95% CI) p-value 
Flow Type – PF vs CF 0.9 (0.3-3.1) 0.9 1.5 (0.8-2.9) 0.2 
History of Prior Infection 1.7 (0.1-25.8) 0.7 1.9 (1.0-3.4) 0.04 
History of Prior Non-Infection Major AE* 1.3 (0.2-9.1) 0.8 1.9 (1.0-3.8) 0.05 
PF: Pulsatile Flow Device; CF: Continuous Flow Device; AE: Adverse Event 
*
 Major Bleeding, Neurological Dysfunction, or Device Malfunction Event 
a
 approximately 20 events are accounted for in the early phase 
b
 approximately 74 events are accounted for in the constant phase 
 
 
 
 
 
 
 
 
 
 
